Inovio Pharmaceuticals (NASDAQ: INO) stock seems to have returned to a calm period now. The things may not be as bad as imaged when investors calm down and revalue the stock.

Although the U.S. government decided it will halt funding for the Phase 3 segment of the COVID-19 Vaccine trial of the company, I think that the company has enough capital to advance INO-4800 through the Phase 3 segment of the pivotal trial. The company is planning for the Phase 3 trial for its COVID-19 vaccine candidate, INO-4800 outside the U.S., but it's not clear which country the company would select.

INO-4800 is the only nucleic-acid based vaccine, and it can be stored for more than one year at room temperature. That's a very important point when preparing for mass vaccination. The decision of the U.S. government does not reflect the safety and efficacy of the company's COVID-19 vaccine candidate, INO-4800. The company may disclose more information about the development of its vaccine in its first quarter 2021 financial result next month, perhaps, it's not a good time for making any decisions on the stock.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.